Cefaclor Anhydrous
The anhydrous form of cefaclor is a second-generation cephalosporin antibiotic with the same antibacterial spectrum and mechanism as the parent compound. It is used to treat mild to moderate infections of the respiratory tract, skin, and urinary tract. This form contains no bound water molecules and is equivalent in activity to the standard formulation.
Molekularmasse
367,8000 g/mol
LogP
-1,80
TPSA
138,00 Ų
Lipinski-Regel der Fünf
Bestanden
Wirkmechanismus
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
2D-Struktur
Cite this structure
Embed this structure
SMILES
N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1
InChI
InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1
Molecular Formula
C15H14ClN3O4S
HBD / HBA
3 / 6
Rotierbare Bindungen
4
Schwere Atome
24
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
The anhydrous form of cefaclor is a second-generation cephalosporin antibiotic with the same antibacterial spectrum and mechanism as the parent compound. It is used to treat mild to moderate infections of the respiratory tract, skin, and urinary tract. This form contains no bound water molecules and is equivalent in activity to the standard formulation.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Cefaclor Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL680. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 51039. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cefaclor-anhydrous"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cefaclor-anhydrous/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cefaclor-anhydrous/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cefaclor-anhydrous/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cefaclor-anhydrous"></drugfyi-drug>